Personalized Prescriptions help you face Obesity and Type 2 Diabetes

Personalized Prescriptions help you face Obesity and Type 2 Diabetes ...

Researchers from Canada and Germany are working together to identifie new medication methods to treat people with obesity and Type 2 diabetes.

The purpose of this program is to develop personalized medicines that are more effective than single medications, and which may potentially replace more invasive treatments, such as bariatric surgery, especially for children.

I can tell you that as a pediatric endocrinologist, we have seen more and more Type 2 diabetes in children and adolescents, and this is more aggressive form than adult-onset diabetes, so we do need better therapies to achieve greater efficiency and weight loss, according toAndrea Haqq, who is also a professor in theAgricultural, Life & Environmental Sciences.

Recent research has published a paper which examines the potential of several medications that contain incretins. These metabolic hormones stimulate the body to produce insulin and use it effectively. They also suppress appetite to control blood sugars and reduce weight.

The researchers say that combining the drugs has several advantages, including that it is beneficial for at least some patients and less side effects.

According to Haqq, our group is dedicated to finding synergistic combinations of therapies for obesity and Type 2 diabetes, which are common comorbid disorders.

Even a five-fold weight gain is considered clinically significant, and patients in some of the combination drugs are achieving 10 or 15 percent, according to Haqq, who is a member of theAlberta Diabetes Institute and theWomen and Childrens Health Research Institute.

Taking research from bench to bedside

Haqqslaboratoryis working with Tamami Muller, director of theInstitute for Diabetes and Obesityat theHelmholtz Diabetes Center, and a researcher at the German Diabetes Research Center in Munich, Germany.

Dr. Muller is a basic scientist who focuses on in vitro or animal models of disease, and he is a clinician scientist who treats many patients with obesity and diabetes, and works with clinical trials. This collaboration allows us to broaden translational medicine and provide a unique perspective on precision therapy.

As part of the Muller collaboration, first authorQiming Tan, a PhD candidate in the Faculty of Medicine & Dentistry, will study for a term in Germany, and a German student will join the Haqqs lab at the U of A.

Further research should be done to elucidate why some individuals respond differently to the drugs. Some racial and ethnic groups are causing a disproportionate burden of obesity and Type 2 diabetes, according to Haqq and Tan, so additional individuals should be involved in trials. Besides, further studies should focus on how biological sex affect drug efficacy and safety.

Out of drug combinations, researchers are looking for non-pharmacological solutions, such as how adding fiber to a person diet can slow weight gain and improve the effectiveness of existing diabetes medications.

The study was funded by the Alberta Diabetes Institute, the International Helmholtz Research School for Diabetes, and the Weston Family Foundation. Haqq has been involved in non-related clinical trials for Rhythm Pharmaceuticals and Levo Therapeutics.

You may also like: